Multiple heterogeneous targets

Multiple heterogeneous targets is a descriptive term used in pharmacology to indicate that a drug or compound exerts its effects by binding to a variety of distinct and often unrelated molecular entities, such as different classes of receptors, enzymes, and ion channels. This phenomenon, known as polypharmacology, is frequently observed with dirty drugs like clozapine or certain multi-kinase inhibitors, where the therapeutic benefit is derived from the cumulative effect on multiple pathways (Nature Reviews Drug Discovery, 2004). While polypharmacology can be advantageous for treating complex, multifactorial diseases like schizophrenia or cancer, the term itself does not represent a valid, single therapeutic target for drug discovery purposes. It serves as a collective label rather than a specific biological identifier, making it difficult to characterize using standard molecular biology techniques. Consequently, this entry is classified as incorrect or non-specific, as it lacks the molecular precision required to define a specific biological mechanism or to guide targeted therapy development (Pharmacological Reviews, 2019). The use of such broad terminology is generally discouraged in structured biochemical databases in favor of listing individual, well-defined proteins.

Other names

PolypharmacologyMulti-target ligandsDirty drugsNon-specific targetsPromiscuous binding

Not applicable; refers to the simultaneous modulation of various unrelated biological targets rather than a single mechanism.